Moderate Psoriasis - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 76 pages report, published by Global Markets Direct

Keywords : Moderate Psoriasis Therapeutic Products under Development, Key Players in Moderate Psoriasis Therapeutics, Moderate Psoriasis Pipeline Overview, Moderate Psoriasis Pipeline, Moderate Psoriasis Pipeline Assessment

Report ThumbnailSeptember-2013
Moderate Psoriasis - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Moderate Psoriasis - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Moderate Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Moderate Psoriasis. Moderate Psoriasis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Moderate Psoriasis.
- A review of the Moderate Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Moderate Psoriasis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Moderate Psoriasis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Moderate Psoriasis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Moderate Psoriasis, H2 2013 8
  • Products under Development for Moderate Psoriasis - Comparative Analysis, H2 2013 9
  • Products under Development by Companies, H2 2013 10
  • Late Stage Products, H2 2013 12
  • Mid Clinical Stage Products, H2 2013 13
  • Early Clinical Stage Products, H2 2013 14
  • Pre-Clinical Stage Products, H2 2013 15
  • Assessment by Monotherapy Products, H2 2013 26
  • Assessment by Route of Administration, H2 2013 27
  • Assessment by Stage and Route of Administration, H2 2013 28
  • Assessment by Molecule Type, H2 2013 29
  • Assessment by Stage and Molecule Type, H2 2013 30
  • List of Tables
  • Number of Products Under Development for Moderate Psoriasis, H2 2013 8
  • Products under Development for Moderate Psoriasis - Comparative Analysis, H2 2013 9
  • Number of Products under Development by Companies, H2 2013 11
  • Comparative Analysis by Late Stage Development, H2 2013 12
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 13
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 14
  • Comparative Analysis by Pre-Clinical Stage Development, H2 2013 15
  • Products under Development by Companies, H2 2013 16
  • Johnson & Johnson, H2 2013 17
  • Boehringer Ingelheim GmbH, H2 2013 18
  • Amgen Inc., H2 2013 19
  • Eli Lilly and Company, H2 2013 20
  • AbGenomics International, Inc., H2 2013 21
  • OPKO Health, Inc., H2 2013 22
  • Idera Pharmaceuticals, Inc., H2 2013 23
  • Almirall, S.A., H2 2013 24
  • Vascular Biogenics Ltd., H2 2013 25
  • Assessment by Monotherapy Products, H2 2013 26
  • Assessment by Stage and Route of Administration, H2 2013 28
  • Assessment by Stage and Molecule Type, H2 2013 30
  • Moderate Psoriasis Therapeutics - Drug Profile Updates 55
  • Moderate Psoriasis Therapeutics - Discontinued Products 70
  • Moderate Psoriasis Therapeutics - Dormant Products 71
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 5
  • Introduction 6
  • Global Markets Direct Report Coverage 6
  • Moderate Psoriasis Overview 7
  • Therapeutics Development 8
  • An Overview of Pipeline Products for Moderate Psoriasis 8
  • Moderate Psoriasis Therapeutics under Development by Companies 10
  • Late Stage Products 12
  • Comparative Analysis 12
  • Mid Clinical Stage Products 13
  • Comparative Analysis 13
  • Early Clinical Stage Products 14
  • Comparative Analysis 14
  • Pre-Clinical Stage Products 15
  • Comparative Analysis 15
  • Moderate Psoriasis Therapeutics - Products under Development by Companies 16
  • Companies Involved in Moderate Psoriasis Therapeutics Development 17
  • Johnson & Johnson 17
  • Boehringer Ingelheim GmbH 18
  • Amgen Inc. 19
  • Eli Lilly and Company 20
  • AbGenomics International, Inc. 21
  • OPKO Health, Inc. 22
  • Idera Pharmaceuticals, Inc. 23
  • Almirall, S.A. 24
  • Vascular Biogenics Ltd. 25
  • Moderate Psoriasis - Therapeutics Assessment 26
  • Assessment by Monotherapy Products 26
  • Assessment by Route of Administration 27
  • Assessment by Molecule Type 29
  • Drug Profiles 31
  • brodalumab - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • AMG-811 - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • AMG-557 - Drug Profile 35
  • Product Description 35
  • Mechanism of Action 35
  • R&D Progress 35
  • ixekizumab - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • ixekizumab - Drug Profile 37
  • Product Description 37
  • Mechanism of Action 37
  • R&D Progress 37
  • IMO-3100 - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • AbGn-168H - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • VB-201 - Drug Profile 41
  • Product Description 41
  • Mechanism of Action 41
  • R&D Progress 41
  • lunacalcipol - Drug Profile 43
  • Product Description 43
  • Mechanism of Action 43
  • R&D Progress 43
  • guselkumab - Drug Profile 45
  • Product Description 45
  • Mechanism of Action 45
  • R&D Progress 45
  • guselkumab - Drug Profile 47
  • Product Description 47
  • Mechanism of Action 47
  • R&D Progress 47
  • HO/02/10 - Drug Profile 49
  • Product Description 49
  • Mechanism of Action 49
  • R&D Progress 49
  • Apo-805-K1 - Drug Profile 50
  • Product Description 50
  • Mechanism of Action 50
  • R&D Progress 50
  • BI-655066 - Drug Profile 51
  • Product Description 51
  • Mechanism of Action 51
  • R&D Progress 51
  • IMO-8400 - Drug Profile 52
  • Product Description 52
  • Mechanism of Action 52
  • R&D Progress 52
  • LAS-41008 - Drug Profile 54
  • Product Description 54
  • Mechanism of Action 54
  • R&D Progress 54
  • Moderate Psoriasis Therapeutics - Drug Profile Updates 55
  • Moderate Psoriasis Therapeutics - Discontinued Products 70
  • Moderate Psoriasis Therapeutics - Dormant Products 71
  • Moderate Psoriasis - Product Development Milestones 72
  • Featured News & Press Releases 72
  • Oct 15, 2012: Idera Pharma Completes Patient Enrollment In Phase II Trial Of IMO-3100 In Patients With Psoriasis 72
  • Mar 28, 2012: Amgen Announces Publication Of Phase II Study Results Of Brodalumab For Treatment Of Psoriasis In New England Journal Of Medicine 73
  • Appendix 75
  • Methodology 75
  • Coverage 75
  • Secondary Research 75
  • Primary Research 75
  • Expert Panel Validation 75
  • Contact Us 76
  • Disclaimer 76

Please select a license type

Share

Related Products

Global Markets DirectModerate Psoriasis - Pipeline Review, H2 2013Product ThumbnailModerate Psoriasis - Pipeline Review, H2 2013, Industry ReportProduct #: 113309
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved